Iron Absorption From Iron Enriched Aspergillus Oryzae in Females Using Stable Isotope Methodology

July 19, 2018 updated by: Dr. Manju B. Reddy, Iowa State University

Iron Absorption From Iron Enriched Aspergillus Oryzae in Females Using Stable Iron Isotope Methodology.

The objective of this study was to compare the iron absorption from ferric pyrophosphate enriched Aspergillus oryzae (ASP-p) to commonly used ferric pyrophosphate (FePP) and ferrous sulfate (FeSO4) when fortified in chicken bouillon, using stable isotope methodology.

Study Overview

Detailed Description

Iron deficiency anemia (IDA) remains the most common nutrient deficiency, globally. Consequences such as decreased cognition, growth impairment, and morbidity and mortality arise from inadequate iron intake. Many technological challenges are presented in fortifying foods with iron, as inorganic iron salts are known to cause organoleptic problems in the food. As a result, finding an iron fortificant that doesn't alter taste, smell or stability of the food is ideal, however most suitable iron fortificants contain low bioavailability. Thirty-five non-anemic female subjects with ferritin ≤ 40 µg/L were recruited for both studies (17 in study I; 18 in study II). In both studies, each meal contained a total of 4.2 mg of added iron fortificants to a test meal containing 6.6 g of chicken bouillon. Participants were randomized to consume either meal A or B, followed by B or C. In study I, subjects consumed a total of 10 mg 57Fe as FePP and 2 mg 58Fe as ASP-p each over three consecutive days. Study II, subjects consumed a total of 10 mg 57Fe as FeSO4 and 2 mg 58Fe as ASP-p over 2 weekends. Blood samples collected at baseline were used to measure iron status indicators such as serum ferritin, C-reactive protein, hepcidin and hematocrit. Fourteen days following final isotope dosing, whole blood samples were collected and the fractional iron absorption of each iron fortificant containing labelled stable isotopes was measured via thermal ionization mass spectrometry with estimation of 80% incorporation into the hemoglobin.

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 33 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Suboptimal iron stores (Serum ferritin < 40 µg/L)
  • BMI in range 18.5 - 24.9 kg/m2
  • Willing to consumed meals containing iron supplement
  • Willing to discontinue blood donation two weeks prior and during the study
  • Willing to discontinue vitamin and mineral supplement use during the study
  • Willing to provide a 15 ml blood for initial screening and 30 ml blood during the study (15 ml at each visit for 2 times in 24 days)
  • Willing to attend 8 lab visits during the study

Exclusion Criteria:

  • Pregnant
  • Lactating
  • Smoker
  • Anemic (hemoglobin < 120 g/L)
  • Has gastrointestinal disease/condition that can affect absorption
  • Vegetarian
  • Allergic to corn, wheat, soybean nor fungal supplements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Ferric pyrophosphate

Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.

  • 57FePP (95.8%) 3.49 mg
  • Aspergillus oryzae (unenriched) 0.025 mg
  • FePP natural abundance 0.685 mg.

Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption.

57 Iron isotopically labeled FePP powder.
Experimental: Aspiron

The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.

  • ASP-p (8% Fe; natural abundance) 3.516 mg
  • 58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg
  • 4.2 total mg of Fe
58 Iron isotope intrinsically labeled Aspergillus oryzae.
Other: Ferrous sulfate

The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .

  • Aspergillus oryzae (unenriched) 0.027 mg
  • 57FeSO4 (95.4%) 3.18 mg
  • 4.2 total mg of Fe
57 Iron isotopically labeled FeSO4 powder.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage Fractional Iron absorption of FePP, FeS)4 and ASP
Time Frame: Whole blood collected 14 days following isotope consumption to allow for enrichment.
Isotope enrichment in the whole blood samples after 14 days of feeding the meals assuming 80% incorporation of iron into the hemoglobin. Circulating iron was calculated from blood volume, height (cm), weight (kg) and hemoglobin (g/dL).
Whole blood collected 14 days following isotope consumption to allow for enrichment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 28, 2016

Primary Completion (Actual)

May 3, 2017

Study Completion (Actual)

June 20, 2017

Study Registration Dates

First Submitted

July 6, 2018

First Submitted That Met QC Criteria

July 6, 2018

First Posted (Actual)

July 13, 2018

Study Record Updates

Last Update Posted (Actual)

July 23, 2018

Last Update Submitted That Met QC Criteria

July 19, 2018

Last Verified

August 1, 2016

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Publish results in a journal.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron Absorption

Clinical Trials on Ferric pyrophosphate

3
Subscribe